Botox treatment for chronic migraine is subsidized under the PBS (Pharmaceutical Benefits Scheme) in Australia for adult patients who meet specific criteria:

1. An average of 15 or more headache days per month, with at least 8 of those being migraine days, over at least 6 months.
2. Inadequate response, intolerance, or contraindication to at least three migraine prophylactic medications.

To continue receiving PBS-covered Botox treatment, a neurologist must confirm a positive response after two treatment cycles (each lasting 12 weeks). A positive response is defined as a 50% or greater reduction in the number of monthly headache days by week 24.

If someone stops Botox treatment—for instance, to try a different approach or because their symptoms have improved—they can potentially resume treatment later. However, this would require a reassessment by a neurologist. If the individual once again meets the PBS criteria and the neurologist determines that Botox is an appropriate treatment option, it may be restarted.

Each case is unique, so consultation with a healthcare professional is essential to determine the best course of action regarding starting or stopping botox treatment.

Please view the government PBS website for current information regarding botox.